CD81 and autoimmune disease: However, the recently reported structures of the IgM- and IgG-BCRs, and the BCR co-receptors CD19, CD81 and CD22 will help guide the rational design of antibodies, nanobodies, and miniproteins for the treatment of B cell malignancies and autoimmune diseases.